Introduction {#bdra23540-sec-0005}
============

Nonsyndromic cleft lip with or without cleft palate (NSCL/P) is one of the commonest birth malformations and varies by geographic origin and ethnicity (Bender, [2000](#bdra23540-bib-0006){ref-type="ref"}). The incidence is approximately 1 in 500 live births in Asia and America, 1 in 1000 in Europe, and 1 in 2500 in Africa. Cleft lip without cleft palate is more frequent in males than females, with a ratio of 2:1, and frequently occurs on the left rather than right side (Mossey et al., [2009](#bdra23540-bib-0046){ref-type="ref"}).

Patients with NSCL/P suffer from functional and cosmetic problems, and NSCL/P can affect speech and communication, which results in delayed development, low self‐confidence, and poor quality of life for both patient and family members. Although reconstruction with maxillo‐facial surgery is possible, severe cases sometimes require multiple corrective surgeries (e.g., cheiloplasy, palatoplasty, rhinoplasty, orthognathicsurgery), dental work, and speech rehabilitation. Thus, this condition places a significant burden on family and medical services (Strauss, [1999](#bdra23540-bib-0096){ref-type="ref"}; Murray, [2002](#bdra23540-bib-0048){ref-type="ref"}).

There have been attempts to identify disease genes associated with NSCL/P as identification of disease genes may shed light on the etiology of the condition and facilitate efforts at prevention of disease. Mutations of interferon regulatory factor 6 (*IRF6*), located on chromosome ***1q32.2*** (OMIM \# 607199), is associated with the autosomal‐dominant Van der Woude syndrome, the most common Mendelian syndrome that has the cardinal signs of cleft lip with or without cleft palate (CL/P) and/or cleft palate only (CPO) with dental anomalies and pitted lips (Kondo et al., [2002](#bdra23540-bib-0036){ref-type="ref"}; Rizos and Spyropoulos, [2004](#bdra23540-bib-0056){ref-type="ref"}). Polymorphisms in *IRF6* were later identified by Zucchero et al. ([2004](#bdra23540-bib-0062){ref-type="ref"}) and replicated by individual studies (Zucchero et al., [2004](#bdra23540-bib-0062){ref-type="ref"}; Rahimov et al., [2008](#bdra23540-bib-0053){ref-type="ref"}; Birnbaum et al., [2009b](#bdra23540-bib-0008){ref-type="ref"}) and genome‐wide association studies (Birnbaum et al., [2009b](#bdra23540-bib-0008){ref-type="ref"}; Grant et al., [2009](#bdra23540-bib-0021){ref-type="ref"}; Beaty et al., [2010](#bdra23540-bib-0005){ref-type="ref"}; Ludwig et al., [2012](#bdra23540-bib-0043){ref-type="ref"}), as associated with NSCL/P. Animal studies also indicate that IRF6 is involved in proliferation‐differentiation of the keratinocyte (Richardson et al., [2009](#bdra23540-bib-0054){ref-type="ref"}), and hyper‐proliferation of the epidermis may result in failure of terminal differentiation and multiple epithelial adhesion leading to CL/P (Ingraham et al., [2006](#bdra23540-bib-0029){ref-type="ref"}; Richardson et al., [2006](#bdra23540-bib-0055){ref-type="ref"}).

A genome‐wide association study of German subjects of Central European origin identified 146 polymorphisms in the 8q24 region, of which rs987525 (OMIM \# 612858) was the most significantly associated with NSCL/P and was the major susceptibility locus in the general population (Birnbaum et al., [2009b](#bdra23540-bib-0008){ref-type="ref"}). Grant et al. ([2009](#bdra23540-bib-0021){ref-type="ref"}) also conducted a case--control genome‐wide association studies (GWAS) in the United States and confirmed the associations of this region. In addition, Beaty et al. ([2010](#bdra23540-bib-0005){ref-type="ref"}) had replicated the GWAS in Asian subjects and had similar results, that is rs987525 was the most significant polymorphism. However, the biological mechanism of this SNP remains unclear.

Several independent studies replicated the effects of the *IRF6* gene (at rs2235371 and rs642961) and the 8q24 region (at rs987525) on NSCL/P, and their effects were later pooled by a meta‐analysis (Wang et al., [2012](#bdra23540-bib-0078){ref-type="ref"}). However, this meta‐analysis pooled only allele effects rather than genotypic effects, which assumes an additive mode of action. In addition, further studies have been published since then. We, therefore, performed an updated meta‐analysis on the same polymorphisms with additional *IRF6* polymorphisms at rs2013162 aiming to assess both variant effects and possible genetic models.

Materials and Methods {#bdra23540-sec-0006}
=====================

Search Strategy {#bdra23540-sec-0007}
---------------

This review was conducted following the HuGE Review guideline (Little and Higgins, [2006](#bdra23540-bib-0041){ref-type="ref"}; Gwinn et al., [2014](#bdra23540-bib-0022){ref-type="ref"}). Studies were identified by two reviewers (K.W. and S.R.) using Medline (by means of PubMed) and Scopus (Sci Verse Scopus; Elsevier B.V.) databases up to February 15, 2016. Search terms used were as follows: (irf6 or irf‐6 or "interferon regulatory factor 6" or "interferon regulation factor‐6" or 8q24) and (polymorphism or gene or allele or SNP) and (NSCL/P or "cleft lip" or CL or "cleft palate" or CP or CPO or "nonsyndromic cleft"). Details of the search strategies are described in Supplementary Table 1, which is available online.

Inclusion and Exclusion Criteria {#bdra23540-sec-0008}
--------------------------------

Two reviewers (K.W. and S.R.) independently selected studies by looking through all titles and abstracts of the identified studies. Any human population‐based (not familial‐based) association study published in English was included if it met the following criteria: the outcome of interest was NSCL/P, the studied polymorphisms were in *IRF6* or 8q24, and sufficient data were reported, that is, allele/genotype frequency between case and control; or odds ratio (OR) of allele/genotype effects on outcome along with its 95% confidence interval (CI). The studies with insufficient information were excluded if authors did not provide data after two contacts. Where there were multiple publications with the same or overlapping subjects (which could be detected by incorporating information on authorship lists, setting, study period, genotyping method, and subjects) the most complete and/or recent results were used. The reference lists of the selected articles were also reviewed to identify additional relevant publications.

Data Extraction {#bdra23540-sec-0009}
---------------

Summary data for *IRF6* and 8q24 were extracted independently by two reviewers (K.W. and S.R.) using a standardized data extraction form. Data on co‐variables, for example, mean age, percentage of males, ethnicity, and family history were also extracted. The main data (generic data and risk of bias assessment) were computerized separately by reviewer. Then, the two data were compared and validated to identify disagreement between. Meetings between the two reviewers (K.W. and S.R.) and the third party (A.T.) were then setup to discuss and solve disagreement.

Risk of Bias Assessment {#bdra23540-sec-0010}
-----------------------

The quality of studies was independently assessed by 2 reviewers (K.W. and S.R.) using a risk of bias assessment for genetic association studies, described in detail previously (Thakkinstian et al., [2005b](#bdra23540-bib-0072){ref-type="ref"}, [2011](#bdra23540-bib-0073){ref-type="ref"}). Briefly, the assessment considered five domains: selection bias, information bias, population stratification, selective reports, and assessment of Hardy‐Weinberg equilibrium (HWE). Each item was classified as yes, no, or unclear, corresponding to low risk of bias, high risk of bias, or unclear/insufficient information. Disagreement was solved by discussion with senior author (A.T.).

Outcome and Studied Gene of Interests {#bdra23540-sec-0011}
-------------------------------------

Our review focused on NSCL/P as the outcomes of interest, which diagnosed according to original studied. The studied genes were three polymorphisms within the *IRF6* gene (rs2235371 G\>A, rs642961 G\>A, and rs2013162 C\>A), and one located within 8q24 (rs987525 C\>A).

Statistical Analysis {#bdra23540-sec-0012}
--------------------

Data analysis was performed following a standard method of meta‐analysis for genetic association studies (Thakkinstian et al., [2005a](#bdra23540-bib-0098){ref-type="ref"}, [2012](#bdra23540-bib-0097){ref-type="ref"}). HWE was checked in control groups for case‐control studies using the Fisher\'s exact test. Data were then pooled based on studies that complied with HWE and if there were at least three studies for each studied polymorphism. A prevalence of minor allele frequency (MAF) for each polymorphism was estimated for each study, and then pooled across studies separately by ethnicity (Thakkinstian et al., 2005b).

Variant effects on NSCL/P were assessed using a per‐allele and per‐genotype approach. For the per‐allele approach, an OR of a versus A, if a and A were, respectively, minor and major alleles, along with its variance were estimated. Heterogeneity was then assessed using Cochrane\'s Q test and *I^2^* statistic. The ORs were then pooled using a random‐effect model by Der Simonian & Laird method if heterogeneity was present (*p* value \< 0.10 or *I^2^* ≥ 25%); otherwise a fixed‐effect model with inverse‐variance method was applied.

For the per‐genotype approach, OR~1~ (aa vs. AA) and OR~2~ (Aa vs. AA) were estimated for each polymorphism across included studies. Heterogeneity was then assessed using the same methods described above. If any of the two ORs was heterogeneous, data were then pooled using a mixed‐effect hierarchical logit model (Thakkinstian et al., [2012](#bdra23540-bib-0097){ref-type="ref"}). In this model, the genotypes were considered as fixed effects, whereas the study was considered as a random effect. A likelihood ratio test was used to assess whether an overall variant effect was significant. The pooled ORs along with 95% CI were then estimated by exponential coefficients of the mixed‐effect logit model. If the overall variant effect was present, the mode of genetic effect was captured by the parameter lambda (λ = logOR~2~ /logOR~1~), which was then estimated using the model‐free Bayesian approach (Minelli et al., [2005](#bdra23540-bib-0045){ref-type="ref"}). The estimated λ (range: 0 to 1) would suggests a recessive, dominant, and additive effect if λ closes to 0, 1, and 0.5, respectively.

A sensitivity analysis was performed by including studies not observing HWE in the main pooling. Publication bias was assessed using the Egger\'s test and funnel plot (Egger et al., [1997](#bdra23540-bib-0017){ref-type="ref"}). In addition, contour enhanced‐funnel plots were generated if there was any evidence of asymmetry suggested by funnel plot or Egger\'s test (Peters et al., [2008](#bdra23540-bib-0052){ref-type="ref"}).

Analyses were performed using STATA version 14 (StataCorp, [2013](#bdra23540-bib-0095){ref-type="ref"}; van Rooij et al., [2004](#bdra23540-bib-0075){ref-type="ref"}) and WinBugs 1.4.2 (Spiegelhalter et al., [2007](#bdra23540-bib-0068){ref-type="ref"}) with normal vague prior distributions for estimation of lambda and ORs. The model was run with 1000 iteration burn in, following by 10,000 iterations for estimation of parameters. A *p*‐value less than 0.05 was considered statistically significant, except for tests of heterogeneity where a level of 0.10 was used. In addition, Bonferroni correction was applied to adjust for 27 multiple tests in total (see Supplementary Table 2), which resulted in a Bonferroni corrected threshold of 1.85 × 10^‐3^.

Results {#bdra23540-sec-0013}
=======

Identifying Studies {#bdra23540-sec-0014}
-------------------

A total of 307 and 1155 studies were, respectively, located from Medline by means of PubMed and Scopus (Fig. [1](#bdra23540-fig-0001){ref-type="fig"}). After 282 duplicates were removed, 1180 studies were screened on titles or abstracts, and 34 studies were eligible. Reasons for ineligibility are provided in Figure [1](#bdra23540-fig-0001){ref-type="fig"}, but were mainly nonrelevant genes or populations, and nongenetic association studies. For studies meeting inclusion criteria, the study by Letra et al. ([2012](#bdra23540-bib-0038){ref-type="ref"}) had insufficient data but the author provided additional data after our request. Studied polymorphisms and number of studies for each polymorphism are described in Figure [1](#bdra23540-fig-0001){ref-type="fig"}. Among them, three polymorphisms (i.e., rs2235371, rs2013162, rs642961) for *IRF6*, and one polymorphism (i.e., rs987525) for 8q24 had sufficient numbers of studies; therefore, further pooling was focused on only these polymorphisms from 31 studies.

![Flow chart for searching.](BDRA-106-773-g001){#bdra23540-fig-0001}

The characteristics of these 31 studies (Srichomthong et al., [2005](#bdra23540-bib-0069){ref-type="ref"}; Rahimov et al., [2008](#bdra23540-bib-0053){ref-type="ref"}; Jugessur et al., [2008](#bdra23540-bib-0032){ref-type="ref"}; Ali et al., [2009](#bdra23540-bib-0002){ref-type="ref"}; Birnbaum et al., [2009a](#bdra23540-bib-0007){ref-type="ref"}, [2009b](#bdra23540-bib-0008){ref-type="ref"}; Grant et al., [2009](#bdra23540-bib-0021){ref-type="ref"}; Huang et al., [2009](#bdra23540-bib-0027){ref-type="ref"}; Nikopensius et al., [2009](#bdra23540-bib-0049){ref-type="ref"}; Tang et al., [2009](#bdra23540-bib-0071){ref-type="ref"}; Carter et al., [2010](#bdra23540-bib-0012){ref-type="ref"}; Mostowska et al., [2010](#bdra23540-bib-0047){ref-type="ref"}; Pan et al., [2010](#bdra23540-bib-0050){ref-type="ref"}; Paranaiba et al., [2010](#bdra23540-bib-0051){ref-type="ref"}; Rojas‐Martinez et al., [2010](#bdra23540-bib-0057){ref-type="ref"}; Shi et al., [2011](#bdra23540-bib-0065){ref-type="ref"}; Weatherley‐White et al., [2011](#bdra23540-bib-0059){ref-type="ref"}; Brito et al., [2012a](#bdra23540-bib-0009){ref-type="ref"}, [2012b](#bdra23540-bib-0010){ref-type="ref"}; Letra et al., [2012](#bdra23540-bib-0038){ref-type="ref"}; Xu et al., [2012](#bdra23540-bib-0061){ref-type="ref"}; Velazquez‐Aragon et al., [2012](#bdra23540-bib-0076){ref-type="ref"}; Hikida et al., [2012](#bdra23540-bib-0024){ref-type="ref"}; Bagordakis et al., [2013](#bdra23540-bib-0004){ref-type="ref"}; Song et al., [2013](#bdra23540-bib-0070){ref-type="ref"}; Lu et al., [2013](#bdra23540-bib-0042){ref-type="ref"}; Aldhorae et al., [2014](#bdra23540-bib-0001){ref-type="ref"}; Krasone et al., [2014](#bdra23540-bib-0037){ref-type="ref"}; do Rego Borges et al., [2015](#bdra23540-bib-0016){ref-type="ref"}; Kerameddin et al., [2015](#bdra23540-bib-0035){ref-type="ref"}; Mijiti et al., [2015](#bdra23540-bib-0044){ref-type="ref"}) are given in Table [1](#bdra23540-tbl-0001){ref-type="table-wrap"}. All studies were case--control designs. Thirteen, 11, and 7 studies were conducted in Asian, Caucasian, and mixed populations. Mean age ranged from approximately 2.6 to 17.3 years, and percent male ranged from 46% to 74%. Fifteen, 9, 11, and 12 studies reported data on rs2235371, rs2013162, rs642961 for *IRF6*, and rs987525 for 8q24, with the outcome NSCL/P, respectively.

###### 

Characteristics of Included Studies

  Author              Year   Country             Ethnicity   Study design   SNP         Locus    Percentage male   Percentage CLO
  ------------------- ------ ------------------- ----------- -------------- ----------- -------- ----------------- ----------------
  Srichomthong C.     2005   Thai                Asian       Case‐control   rs2235371   *IRF6*   0.58              0.38
  Jugessur A.         2008   Norway              Caucasian   Case‐control   rs2235371   *IRF6*                     
                                                                            rs2013162   *IRF6*                     
  Rahimov F.          2008   Norway, Denmark     Caucasian   Case‐control   rs642961    *IRF6*                     0.4
  Ali A.              2009   India               Asian       Case‐control   rs2235371   *IRF6*   0.7               
  Birnbaum S.         2009   Central Europe      Caucasian   Case‐control   rs2235371   *IRF6*                     
                                                                            rs2013162   *IRF6*                     
                                                                            rs642961    *IRF6*                     
  Birnbaum S.         2009   Central Europe      Caucasian   Case‐control   rs987525    8q24                       0.22
  Grant S.            2009   USA                 Caucasian   Case‐control   rs987525    8q24     0.69              
  Huang Y.            2009   China               Asian       Case‐control   rs2235371   *IRF6*                     0.15
                                                                            rs2013162   *IRF6*                     
  Nikopensius T.      2009   Estonia, Lithonia   Caucasian   Case‐control   rs987525    8q24                       
  Tang W.             2009   China               Asian       Case‐control   rs2235371   *IRF6*   0.74              
  Carter TC.          2010   Ireland             Caucasian   Case‐control   rs2235371   *IRF6*                     
                                                                            rs2013162   *IRF6*                     
  Mostowska A.        2010   Poland              Caucasian   Case‐control   rs642961    *IRF6*   0.51              0.11
                                                                            rs987525    8q24                       
  Pan Y.              2010   China               Asian       Case‐control   rs2235371   *IRF6*   0.64              0.4
                                                                            rs642961    *IRF6*                     
  Paranaiba L.        2010   Brazil              Caucasian   Case‐control   rs2235371   *IRF6*                     
                                                                            rs642961    *IRF6*                     
  Rojas‐Martinez A.   2010   Mexico              Mixed       Case‐control   rs987525    8q24                       

  Author                Year   Country   Ethnicity   Study design   SNP         Locus    Mean age   Percentage male   Percentage CLO
  --------------------- ------ --------- ----------- -------------- ----------- -------- ---------- ----------------- ----------------
  Shi J.                2011   China     Asian       Case‐control   rs2235371   *IRF6*   1 to 28    0.46              0.29
                                                                    rs642961    *IRF6*                                
  Weatherley‐White R.   2011   Kenya     Mixed       Case‐control   rs2013162   *IRF6*                                
                                                                    rs987525    8q24                                  
  Brito L.              2012   Brazil    Mixed       Case‐control   rs642961    *IRF6*                                0.19
  Brito L.              2012   Brazil    Mixed       Case‐control   rs987525    8q24                                  
  Hikida M.             2012   Japan     Asian       Case‐control   rs987525    8q24                                  
  Letra A.              2012   Brazil    Caucasian   Case‐control   rs2235371   *IRF6*   17.32      0.6               
                                                                    rs2013162   *IRF6*                                
  Velazquez‐Aragon J.   2012   Mexico    Mixed       Case‐control   rs2235371   *IRF6*                                
                                                                    rs987525    8q24                                  
  Xu M.                 2012   China     Asian       Case‐control   rs987525    8q24     7.95       0.68              0.2
  Bagordakis E.         2013   Brazil    Mixed       Case‐control   rs2013162   *IRF6*                                0.35
  Lu Y.                 2013   China     Asian       Case‐control   rs2235371   *IRF6*                                
                                                                    rs2013162   *IRF6*                                
  Song T.               2013   China     Asian       Case‐control   rs2235371   *IRF6*                                
  Aldhorae KA.          2014   Arab      Asian       Case‐control   rs642961    *IRF6*                                
                                                                    rs987525    8q24                                  
  Krasone K.            2014   Latvia    Caucasian   Case‐control   rs642961    *IRF6*                                
  Do Rego Borges A.     2015   Brazil    Mixed       Case‐control   rs642961    *IRF6*                                
                                                                    rs987525    8q24                                  
  Kerameddin S.         2015   Iran      Asian       Case‐control   rs642961    *IRF6*                                
  Mijiti A.             2015   China     Asian       Case‐control   rs2235371   *IRF6*                                
                                                                    rs2013162   *IRF6*                                

Risk of Bias Assessment {#bdra23540-sec-0015}
-----------------------

The results of bias assessment are presented in Supplementary Table 3. All studies had low risks of bias related to ascertainment of NSCL/P and population stratification. Twenty‐nine of 31 studies assessed HWE. Most studies (97%) had low risk of selective reporting of outcomes. Twenty‐seven (87%) and 24 (77%) studies described control ascertainment and quality control for genotyping, respectively.

rs2235371 {#bdra23540-sec-0016}
---------

Fifteen studies (i.e., 9 Asians, 5 Caucasians, and 1 mixed ethnicity) assessed effect of rs2235371 polymorphism on NSCL/P. Allele frequencies in the NSCL/P and control groups are described, and genotype frequencies in the control groups complied with HWE for all studies (Supplementary Table 4). The MAF was pooled by ethnicity. This suggested the pooled prevalence of MAF A in Asians was 0.34 (95% CI, 0.28--0.40) in the control group and 0.26 (95% CI, 0.19--0.32) in NSCL/P groups, yielding a pooled OR of 0.66 (95% CI, 0.58--0.75, *p* = 1.27 × 10^‐9^), which was still significant based on Bonferroni corrected‐threshold. The MAF A in Caucasians was very rare and much lower than in Asians, that is, 0.03 (95% CI, 0.02--0.04) and 0.02 (95% CI, 0.01--0.04) in control and NSCL/P groups, respectively. This yielded a pooled OR of 0.69 (95%CI, 0.43--1.12; *p* = 0.131), but this was not statistically significant.

The genotype frequencies between NSCL/P (*n* = 3513) and control (*n* = 4756) groups along with ORs for all studies are described in Table [2](#bdra23540-tbl-0002){ref-type="table-wrap"}. Because MAF was different between Asians and Caucasians, pooling genotype effect was, therefore, performed separately by ethnicity. Degrees of heterogeneity *I^2^* for OR~1~ (AA vs. GG) and OR~2~ (GA vs. GG) were, respectively, 60.0% (Chi‐square = 19.98; d.f. = 8; *p* = 0.010) and 0% (Chi‐square = 3.70; d.f. = 8, and *p* = 0.883) for pooling 9 Asian studies (n = 1677 vs. 1717). The corresponding pooled ORs were 0.49 (95% CI, 0.39--0.63; *p* = 7.73 × 10^‐9^) and 0.58 (95% CI, 0.50--0.68; *p* = 1.50 × 10^‐12^), see Figure [2](#bdra23540-fig-0002){ref-type="fig"}A,B. These genotype effects were still significant after applying Bonferroni corrected‐threshold, indicating that carrying AA and GA is associated with approximately 51% and 42% lower odds of having NSCL/P than carrying GG genotype. The estimated lambda was 0.71 (95% CI, 0.38--0.98), indicating that a mode of variant effect could be from additive to dominant effect.

###### 

Genotype Frequencies and Genotype Effects for IRF‐6 at SNPs 2235371 Between NSCL/P and Control Groups

                           CL/P   Control                                                                  
  ----------------- ------ ------ --------- ----- ---- ----- ----- ----- ---- ------ -------------- ------ ------------
  Asian                                                                                                    
  Srichomthong C.   2005   192    93        72    27   278   100   137   41   0.71   0.40, 1.24     0.57   0.38, 0.84
  Ali A.            2009   323    252       65    6    214   141   66    7    0.48   0.16, 1.46     0.55   0.37, 0.82
  Huang Y.          2009   257    133       106   18   174   57    79    38   0.20   0.11, 0.39     0.58   0.38, 0.88
  Tang W.           2009   66     30        31    5    96    34    50    12   0.47   0.15, 1.50     0.70   0.36, 1.37
  Pan Y.            2010   127    69        40    18   115   47    60    8    1.53   0.62, 3.81     0.45   0.26, 0.78
  Shi J.            2011   173    82        69    22   154   63    71    20   0.85   0.42, 1.68     0.75   0.47, 1.19
  Lu Y.             2013   236    122       96    18   400   152   180   68   0.33   0.19, 0.58     0.66   0.47, 0.94
  Song T.           2013   203    114       72    17   226   93    106   27   0.51   0.26, 1.00     0.55   0.37, 0.83
  Mijiti A.         2015   100    80        17    3    60    39    20    1    1.46   0.15, 14.52    0.41   0.20, 0.88
  Pooled                                                                      0.49   0.39, 0.63     0.58   0.50, 0.68
  Caucasian                                                                                                
  Jugessur A.       2008   314    297       17    0    416   399   17    0    1.34   0.03, 67.87    1.34   0.68, 2.65
  Birnbaum S.       2009   442    435       7     0    952   913   39    0    2.10   0.04, 105.89   0.40   0.18, 0.88
  Carter TC.        2010   460    456       4     0    894   869   25    0    1.91   0.04, 96.15    0.34   0.12, 0.92
  Paranaiba LM.     2010   177    159       18    0    126   113   13    0    0.71   0.01, 36.13    0.98   0.46, 2.05
  Letra A.          2012   311    283       26    2    281   245   34    2    0.87   0.12, 6.19     0.66   0.39, 1.13
  Pooled                                                                      0.75   0.27, 1.75     0.82   0.55, 1.16
  Mixed ethnicity                                                                                          
  Velazquez JA.     2012   132    75        50    7    370   163   162   45   0.34   0.15, 0.79     0.67   0.44, 1.02
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Among 5 Caucasian studies (*n* = 1704 and 2669 for NSCL/P and control), heterogeneity was not present in OR~1~ but was present for OR~2~ with an *I^2^* of 0% (Chi‐square = 0.29; d.f. = 4; *p* = 0.990) and 51.9% (Chi‐square = 8.32; d.f. = 4; *p* = 0.080), respectively. The pooled OR~1~ and OR~2~ were 0.75 (95% CI, 0.27--1.75; *p* = 0.506) and 0.82 (95% CI, 0.55--1.16; *p* = 0.262), see Figure [2](#bdra23540-fig-0002){ref-type="fig"}C,D; indicating nonsignificant variant effects for both AA and GA genotypes when compared with GG genotypes.

Publication bias was assessed for both pooled ORs in Asian and Caucasian by funnel plot and Egger\'s test. There was no evidence of asymmetry of the funnel, see Supplementary Figure 1A--D. These results agreed with the Egger\'s tests, which indicated no evidence of asymmetry of funnels for both OR~1~ (coefficient = 1.448; *p* = 0.408) and OR~2~ (coefficient = ‐1.018; *p* = 0.358) in Asian, and OR~1~ (coefficient = 0.480; *p* = 0.261) and OR~2~ (coefficient = ‐2.763; *p* = 0.452) in Caucasian.

rs2013162 {#bdra23540-sec-0017}
---------

Among the nine studies that assessed the association between rs2013162 in IRF6 and NSCL/P, four studies, three studies, and two studies were conducted in Caucasians, Asians, and in mixed ethnicity, respectively. Allele effects were pooled in Caucasian and Asian where numbers were sufficient. All studies complied with HWE with the pooled MAF A of 0.35 (95% CI,0.34--0.37) and 0.42 (95% CI, 0.35--0.50), respectively, in Caucasian, Asian of control populations. The pooled ORs of A versus C alleles were, respectively, 0.84 (95% CI, 0.76--0.93; *p* = 4.16 × 10^‐4^) and 0.99 (95% CI, 0.57--1.73; *p* = 0.974) in Caucasians and Asians (Supplementary Table 5).

The genotype frequency between NSCL/P groups of 9 studies are described in Table [3](#bdra23540-tbl-0003){ref-type="table-wrap"}. Among four Caucasian studies (*n* = 1530 vs. 2511 for NSCL/Ps vs. controls), ORs (i.e., OR~1~ \[AA vs. CC\] and OR~2~ \[CA vs. CC\]) showed low heterogeneity for OR~1~ (Chi‐square = 3.19; d.f. = 3; *p* = 0.363; *I^2^* = 6.1%) and OR~2~ (Chi‐square = 0.57; d.f. = 3; *p* = 0.904; *I^2^* = 0%), see Figure [3](#bdra23540-fig-0003){ref-type="fig"}A,B. The pooled OR~1~ and OR~2~ were, respectively, 0.65 (95% CI, 0.52--0.82; *p* = 1.93 × 10^‐4^) and 0.89 (95% CI, 0.78--1.02; *p* = 0.102), suggesting that the odds of NSCL/P was significantly different in AA genotype even based on Bonferroni corrected threshold, but was not significantly different in CA genotype when compared with CC genotype. The estimated lambda was 0.32 (95% CI, 0.02--0.92), which possibly indicated between a recessive to additive effect of A allele.

###### 

Genotype Frequencies and Genotype Effects for IRF‐6 at SNPs 2013162 Between NSCL/P and Control Groups

                                CL/P   Control                                                                 
  ---------------------- ------ ------ --------- ----- ---- ----- ----- ----- ----- ------ ------------ ------ ------------
  Asian                                                                                                        
  Huang Y.               2009   165    53        84    28   174   51    87    36    0.75   0.40, 1.40   0.93   0.57, 1.51
  Lu Y.                  2013   236    57        132   47   400   156   200   44    2.92   1.75, 4.87   1.81   1.24, 2.63
  Mijiti A.              2015   100    44        41    15   59    16    31    12    0.46   0.18, 1,18   0.48   0.23, 1.01
  Pooled                                                                            1.40   0.97, 2.01   1.20   0.92, 1.57
  Caucasian                                                                                                    
  Jugessur A.            2008   313    136       141   36   416   174   190   52    0.89   0.55, 1.43   0.95   0.69, 1.30
  Birnbaum S.            2009   460    215       210   35   952   410   430   112   0.60   0.39, 0.90   0.93   0.74, 1.18
  Carter TC.             2010   447    204       202   41   861   350   409   102   0.69   0.46, 1.03   0.85   0.67, 1.08
  Letra A.               2012   310    143       140   27   282   110   128   44    0.47   0.28, 0.81   0.84   0.60, 1.19
  Pooled                                                                            0.65   0.52, 0.82   0.89   0.78, 1.02
  Mixed ethnicity                                                                                              
  Weatherley‐White RC.   2011   128    76        45    7    105   56    41    8     0.65   0.22, 1.88   0.81   0.47, 1.40
  Bagordakis E.          2013   233    122       88    23   308   142   137   29    0.92   0.51, 1.68   0.75   0.52, 1.07

![Forest plots for rs2013162 of IRF6.](BDRA-106-773-g003){#bdra23540-fig-0003}

Among three Asian studies (*n* = 501 for NSCL/Ps and 633 for controls), heterogeneity was present in both OR~1~ and OR~2~ with an *I^2^* of 88.4% (Chi‐square = 17.21; d.f. = 2; *p* \< 0.001) and 82.6% (Chi‐square = 11.52; d.f. = 2; *p* = 0.003), respectively. The pooled OR~1~ and OR~2~ were 1.40 (95% CI, 0.97--2.01; *p* = 0.069) and 1.20 (95% CI, 0.92--1.57; *p* = 0.172), see Figure [3](#bdra23540-fig-0003){ref-type="fig"}C,D; indicating nonsignificant variant effects for both AA and CA genotypes when compared with CC genotypes.

Publication bias was assessed for both pooled ORs in Caucasian and Asian by funnel plot and Egger\'s test. Funnel plots suggested little asymmetry (Supplementary Fig. 2A--D), but the Egger\'s test did not confirm this. The coefficients of asymmetry was ‐2.07 (SE = 5.25; *p* = 0.731) for OR~1~ and ‐0.25 (SE = 1.64; *p* = 0.894) for OR~2~ in Caucasian, and ‐8.58 (SE = 5.45; *p* = 0.360) for OR~1~ and ‐7.41 (SE = 1.88; *p* = 0.158) for OR~2~ in Asian.

rs642961 {#bdra23540-sec-0018}
--------

Eleven studies assessed effect of rs642961 polymorphism on NSCL/P. Among them, five studies, four studies, and two studies were conducted in Caucasians, Asians, and mixed ethnicity, respectively. One study (Brito et al., [2012a](#bdra23540-bib-0009){ref-type="ref"}) did not comply with HWE and, thus, excluded from pooling. Data were sufficient for pooling in Caucasians and Asians. The pooled MAF A was 0.19 (95% CI, 0.17--0.22) and 0.17 (95% CI, 0.13--0.22) in Caucasians and Asians, respectively (Supplementary Table 6). The pooled ORs (A vs. G) were 1.50 (95% CI, 1.35--1.68, *p* = 5.11 × 10^‐13^) and 1.47 (95% CI, 1.09--1.98; *p* = 1.10 × 10^‐2^) in Caucasians and Asians, respectively.

The genotype frequencies between NSCL/P and control groups are described in Table [4](#bdra23540-tbl-0004){ref-type="table-wrap"}. Genotype effects were sufficient for pooling in Caucasians and Asians. Among 5 Caucasians studies (*n* = 1244 vs. 3069 for NSCL/Ps and controls), the OR~1~ (AA vs. GG) and OR~2~ (GA vs. GG) were estimated with low heterogeneity for OR~1~ (Chi‐square = 5.31; d.f. = 4; *p* = 0.257; *I^2^* = 24.6%) and moderate for OR~2~ (Chi‐square = 6.08; d.f. = 4; *p* = 0.194; *I^2^* = 34.2%). The mixed‐effect logit model yielded pooled OR~1~ and OR~2~ of 2.03 (95% CI, 1.52--2.71; *p* = 1.81 × 10^‐6^) and 1.58 (95% CI, 1.37--1.82; *p* = 4.59 × 10^‐10^), which suggested that persons with AA and GA genotypes were 2.03 and 1.58 times significantly higher risk of NSCL/P than persons with GG genotype (Fig. [4](#bdra23540-fig-0004){ref-type="fig"}A,B). These effects were still significant based on Bonferroni corrected threshold. The estimated lambda value was 0.62 (95% CI, 0.17--0.96) suggesting a potential mode of effect between recessive to additive effect.

###### 

Genotype Frequencies and Genotype Effects for IRF‐6 at SNPs 642961 Between NSCL/P and Control Groups

                             CL/P   Control                                                                    
  ------------------- ------ ------ --------- ----- ---- ------ ----- ----- ---- ------- -------------- ------ ------------
  Asian                                                                                                        
  Pan Y.              2010   127    67        54    6    115    81    33    1    7.25    0.85, 61.75    1.98   1.15, 3.40
  Shi J.              2011   173    100       62    11   156    111   43    2    6.11    1.32, 28.21    1.60   1.00, 2.57
  Aldhorae KA.        2014   242    159       74    9    420    311   101   8    2.20    0.83, 5.81     1.43   1.00, 2.05
  Kerameddin S.       2015   150    88        51    11   150    84    57    9    1.17    0.46, 2.96     0.85   0.53, 1.38
  Pooled                                                                         2.47    1.41, 4.35     1.40   1.12, 1.75
  Caucasian                                                                                                    
  Rahimov F.          2008   368    180       155   33   1244   757   427   60   2.31    1.47, 3.65     1.53   1.19, 1.95
  Birnbaum S.         2009   460    237       189   34   951    622   283   46   1.94    1.22, 3.10     1.75   1.38, 2.22
  Mostowska A.        2010   165    82        74    9    565    349   184   32   1.20    0.55, 2.61     1.71   1.19, 2.46
  Paranaiba LM.       2010   177    128       45    4    126    90    36    0    6.34    0.34, 119.19   0.88   0.53, 1.47
  Krasone K.          2014   74     41        29    4    183    129   53    1    12.59   1.37, 115.80   1.72   0.97, 3.05
  Pooled                                                                         2.03    1.52, 2.71     1.58   1.37, 1.82
  Mixed ethnicity                                                                                              
  Brito LA.           2012   471    320       123   28   391    285   90    16   1.56    0.83, 2.94     1.22   0.89, 1.67
  do Rego Borges A.   2015   293    214       73    6    352    282   63    7    1.13    0.37, 3.41     1.53   1.04, 2.24
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Among four Asians studies (*n* = 300 vs. 271 for NSCL/Ps and controls), the OR~1~ (AA vs. GG) and OR~2~ (GA vs. GG) were estimated with moderate heterogeneity for OR~1~ (Chi‐square = 4.77; d.f. = 3; *p* = 0.189; *I^2^* = 37.1%) and OR~2~ (Chi‐square = 5.93; d.f. = 3; *p* = 0.115; *I^2^* = 49.4%). The mixed‐effect logit model yielded pooled OR~1~ and OR~2~ of 2.47 (95% CI, 1.41--4.35; *p* = 1.65 × 10^‐3^) and 1.40 (95% CI, 1.12--1.75; *p* = 3.02 × 10^‐3^), which suggested that persons with AA and GA genotypes were 2.47 and 1.40 times significantly higher risk of NSCL/P than persons with GG genotype (Fig. [4](#bdra23540-fig-0004){ref-type="fig"}C,D). However, only OR~1~ was still significant based on Bonferroni corrected threshold. The estimated lambda value was 0.62 (95% CI, 0.17--0.96) suggesting a potential mode of variant effect could be from a recessive to additive mode.

No evidence of reporting bias was seen with either OR~1~ or OR~2~ suggested from Egger tests (in Caucasian: coefficient = 0.98; SE = 0.98; *p* = 0.391 for OR~1~ and coefficient = ‐1.61; SE = 1.68; *p* = 0.409 for OR~2~; in Asian: coefficient = 3.14; SE = 1.22; *p* = 0.124 for OR~1~ and coefficient = 0.66; SE = 5.33; *p* = 0.913 for OR~2~) and funnel plots (Supplementary Fig. 3A--D).

rs987525 {#bdra23540-sec-0019}
--------

Allele frequencies of 12 studies assessed effect of rs987525 polymorphism on NSCL/P and all observed HWE (Supplementary Table 7). The MAF A in controls were 0.15 (95% CI, 0.00--0.31) in three Asian studies, and 0.20 (95% CI, 0.17--0.22) in four Caucasian studies, and 0.27 (95% CI, 0.17--0.38) in five mixed ethnicity. The estimated ORs for allele A versus C in these corresponding ethnicities were 1.48 (95% CI, 1.21--1.81; *p* = 1.21 × 10^‐4^), and 2.20 (95% CI, 1.96--2.46; *p* \< 1.00 × 10^‐12^), and 1.21 (95% CI, 1.09--1.36; *p* = 7.5 × 10^‐4^), respectively.

Among three Asian studies (*n* = 625 in NSCL/P and 811 in controls), the pooled OR~1~ (AA vs. CC) and OR~2~ (CA vs. CC) were, respectively, 2.27 (95% CI, 1.43--3.60; *p* = 4.71 × 10^‐4^) and 1.34 (95% CI, 1.02--1.77; *p* = 3.71 × 10^‐2^), with no heterogeneity for OR~1~ (Chi‐square = 0.10; d.f. = 2; *p* = 0.950; *I^2^* = 0%) and OR~2~ (Chi‐square = 1.83; d.f. = 2; *p* = 0.401; *I^2^* = 0%) (Table [5](#bdra23540-tbl-0005){ref-type="table-wrap"}; Fig. [5](#bdra23540-fig-0005){ref-type="fig"}A,B). This indicates that those with AA and CA genotypes were 2.27 and 1.34 times significantly, based on Bonferroni corrected threshold, more likely to have NSCL/P than those with the CC genotype. The estimated lambda was 0.45 (95% CI, 0.27--0.67), indicating an additive model was most likely.

###### 

Genotype Frequencies and Genotype Effects for 8q24 at SNPs 987525 Between NSCL/P and Control Groups

                                CL/P   Control                                                                     
  ---------------------- ------ ------ --------- ----- ---- ------ ------ ------ ----- ------ ------------- ------ ------------
  Asian                                                                                                            
  Hikida M.              2012   167    145       21    1    190    170    20     0     3.52   0.14, 86.96   1.23   0.64, 2.36
  Xu MY.                 2012   216    188       26    2    200    175    24     1     1.86   0.17, 20.71   1.01   0.56, 1.82
  Aldhorae KA.           2014   242    76        119   47   421    189    186    46    2.54   1.56, 4.13    1.59   1.12, 2.26
  Pooled                                                                               2.27   1.43, 3.60    1.34   1.02, 1.77
  Caucasian                                                                                                        
  Birnbaum S.            2009   462    172       228   62   952    604    312    36    6.05   3.88, 9.43    2.57   2.02, 3.26
  Grant S.               2009   111    45        51    15   5951   3667   2009   275   4.45   2.45, 8.08    2.07   1.38, 3.10
  Nikopensius T.         2009   217    114       82    21   1267   889    353    25    6.55   3.55, 12.08   1.81   1.33, 2.47
  Mostowska A.           2010   165    77        70    18   565    357    186    22    3.79   1.94, 7.41    1.75   1.21, 2.52
  Pooled                                                                               5.25   3.98, 6.91    2.13   1.82, 2.49
  Mixed ethnicity                                                                                                  
  Rojas‐Martinez A.      2010   149    109       31    9    303    231    69     3     6.36   1.69, 23.95   0.95   0.59, 1.54
  Weatherley‐White RC.   2011   129    42        63    24   105    38     50     17    1.28   0.60, 2.73    1.14   0.64, 2.03
  Brito LA.              2012   667    278       302   87   589    284    239    66    1.35   0.94, 1.93    1.29   1.02, 1.64
  Velazquez JA.          2012   132    89        42    1    370    267    91     12    0.25   0.03, 1.95    1.39   0.89, 2.14
  do Rego Borges A.      2015   293    94        143   56   352    141    155    56    1.50   0.95, 2.36    1.38   0.98, 1.96
  Pooled                                                                               1.42   1.10, 1.82    1.28   1.09, 1.50
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Among four Caucasian studies (*n* = 955 in NSCL/P and 8735 in controls), the pooled OR~1~ (AA vs. CC) and OR~2~ (CA vs. CC) were, respectively, 5.25 (95% CI, 3.98--6.91; *p* \< 1.00 × 10^‐12^) and 2.13 (95% CI, 1.82--2.49; *p* \< 1.00 × 10^‐12^), with no heterogeneity for OR~1~ (Chi‐square = 2.09; d.f. = 3; *p* = 0.553; *I^2^* = 0%) and moderate heterogeneity for OR~2~ (Chi‐square = 4.50; d.f. = 3; *p* = 0.212; *I^2^* = 33.3%) (Table [5](#bdra23540-tbl-0005){ref-type="table-wrap"}; Fig. [5](#bdra23540-fig-0005){ref-type="fig"}C,D). This indicates that those with AA and CA genotypes were 5.25 and 2.13 times significantly, based on Bonferroni corrected threshold, more likely to have NSCL/P than those with the CC genotype. The estimated lambda was 0.45 (95% CI, 0.27--0.67), indicating an additive model was most likely.

Among five studies with mixed ethnicity (*n* = 1370 in NSCL/P and 1719 in controls), the corresponding pooled ORs were 1.42 (95% CI, 1.10--1.82; *p* = 6.10 × 10^‐3^) and 1.28 (95% CI, 1.09--1.50; *p* = 2.47 × 10^‐3^) with moderate heterogeneity for OR~1~ (Chi‐square = 7.87; d.f. = 4; *p* = 0.096; *I^2^* = 49.2%) and no evidence of heterogeneity for OR~2~ (Chi‐square = 1.92; d.f. = 4; *p* = 0.751; *I^2^* = 0%) (Fig. [5](#bdra23540-fig-0005){ref-type="fig"}F,G). These two ORs were not significant based on Bonferroni corrected threshold. The estimated lambda 0.68; 95% CI, 0--1), which could possibly be between additive to dominant mode.

There was no evidence of reporting bias (in Asian: Egger coefficient = ‐0.02; SE = 0.28; *p* = 0.951 for OR~1~ and coefficient = ‐2.50; SE = 1.29; *p* = 0.303 for OR~2~; in Caucasian: coefficient = ‐2.76; SE = 2.48; *p* = 0.380 for OR~1~ and coefficient = ‐3.93; SE = 2.47; *p* = 0.252 for OR~2~; in mixed ethnicity: coefficient = 0.10; SE = 1.45; *p* = 0.951 for OR~1~ and coefficient = ‐0.93; SE = 1.00; *p* = 0.422 for OR~2~; see Funnel plots in Supplementary Figure 4A--F.

Discussion {#bdra23540-sec-0020}
==========

We conducted a systematic review and meta‐analysis to assess genetic effects of polymorphisms in *IRF6* and 8q24 region on NSCL/P. A total of 9 to 15 studies were included in the pooling for three polymorphisms (i.e., rs2235371, rs2013162, rs642961) for *IRF6* and for rs987525 in 8q24. The MAF for these corresponding polymorphisms were similar across ethnicities except for rs2235371 where the MAF was common in Asians but rare in Caucasians, whereas MAF for rs987525 was common in Caucasians but less common in Asians. Because the MAF of rs2235371 was different between ethnicities, the genotype effect for this SNP was different. All polymorphisms were significantly associated with NSCL/P in some ethnicities. A significant protective effect of rs2235371 in Asians and effect of rs2013162 in Caucasians were suggested, that is, carrying one copy of the A allele for both polymorphisms lowered the odds of NSCL/P compared with G and C alleles, respectively. In addition, our findings indicated risk effects of minor alleles for rs642961 and rs987525.

Our findings are consistent with previous human GWAS studies (Birnbaum et al., [2009b](#bdra23540-bib-0008){ref-type="ref"}; Grant et al., [2009](#bdra23540-bib-0021){ref-type="ref"}; Beaty et al., [2010](#bdra23540-bib-0005){ref-type="ref"}; Ludwig et al., [2012](#bdra23540-bib-0043){ref-type="ref"}). In addition, our findings are also consistent with the previous meta‐analysis of genetic association studies by Wang et al. (2012), that included 10, 6, and 8 studies in the pooling of rs2235371 and rs642961 for *IRF6*, and rs987525 for 8q24, respectively. We confirmed the previous findings by expanding to a larger number of included genetic association studies (i.e., 15, 11, and 12 studies for these corresponding polymorphisms) and applying Bonferroni correction for multiple tests. Although each polymorphism was considered separately in meta‐analysis for genetic association studies, this type of study had been used to replicate and confirm GWAS. Not only allele effects were estimated, but also pooled MAF and genotype effects by ethnicity additionally provided from previous evidences.

Formation of the lip and palate in human embryos starts at the fourth week and is complete by the twelfth week after fertilization. This process occurs by migration of the ectoderm, and formation of frontal, medial and lateral nasal processes, which then fuse together to form the normal lips and nose (Shkoukani et al., [2013](#bdra23540-bib-0066){ref-type="ref"}). A normal palate also occurs after complete fusion of the primary and secondary palates; failure of fusion causes separation of the lip/s and/or palate, that is, cleft lip and cleft palate, respectively. Although the function of the *IRF6* gene on the cleft lip formation is unclear, evidence has supported an effect of this gene on other birth malformations including Van der Woude syndrome and popliteal pterygium syndrome (Kondo et al., [2002](#bdra23540-bib-0036){ref-type="ref"}; Kayano et al., [2003](#bdra23540-bib-0033){ref-type="ref"}; Shotelersuk et al., [2003](#bdra23540-bib-0067){ref-type="ref"}; Gatta et al., [2004](#bdra23540-bib-0019){ref-type="ref"}; Ghassibé et al., [2004](#bdra23540-bib-0020){ref-type="ref"}; Item et al., [2004](#bdra23540-bib-0030){ref-type="ref"}). High IRF6 mRNA levels are also seen at the medial edge of the fusing palate (Kondo et al., [2002](#bdra23540-bib-0036){ref-type="ref"}).

In addition, evidence from animal studies also supports the role of IRF6 on NSCL/P. Animal models have shown abnormalities of epithelial differentiation in mice with a mutation of *IRF6* (Iwata et al., [2013](#bdra23540-bib-0031){ref-type="ref"}). This supports a role for IRF6 in the formation and maintenance of the periderm, and spatiotemporal regulation for appropriate palatal adhesion (Richardson et al., [2009](#bdra23540-bib-0054){ref-type="ref"}). Another study on mice with mutation of IRF6 showed abnormal skin, limb, and craniofacial development, which suggests a role for IRF6 in keratinocyte proliferation and differentiation of face and limb (Ingraham et al., [2006](#bdra23540-bib-0029){ref-type="ref"}). The role of the 8q24 region on NSCL/P is still unclear but it might be involved in maintenance of an undifferentiated state in human acute myeloblastic leukemia cells (HL60) (Hirano et al., [2008](#bdra23540-bib-0025){ref-type="ref"}), control of Myc expression (Uslu et al., [2014](#bdra23540-bib-0074){ref-type="ref"}), or cranial facial enhancers (Attanasio et al., [2013](#bdra23540-bib-0003){ref-type="ref"}).

The etiology of NSCL/P is still unclear but evidence suggests that both genetic and nongenetic factors play a role (Dixon et al., [2011](#bdra23540-bib-0015){ref-type="ref"}; Shkoukani et al., 2013). Environmental factors may also play a role in NSCL/P. These factors may be independent or they may be modified by genes such as 5, 10‐methylenetetrahydrofolate reductase and folate (Bufalino et al., [2010](#bdra23540-bib-0011){ref-type="ref"}). Evidence from cohort studies suggested that oral folate supplements before or during the periconception period might be able to reduce risk of NSCL/P (van Rooij et al., 2004; Kelly et al., [2012](#bdra23540-bib-0034){ref-type="ref"}; Li et al., [2012](#bdra23540-bib-0039){ref-type="ref"}); this is being confirmed by a randomized controlled trial (Wehby et al., [2012](#bdra23540-bib-0060){ref-type="ref"}). Other factors associated with NSCL/P include alcohol consumption (Lieff et al., [1999](#bdra23540-bib-0040){ref-type="ref"}; DeRoo et al., [2008](#bdra23540-bib-0014){ref-type="ref"}), gestational diabetes (Correa et al., [2008](#bdra23540-bib-0013){ref-type="ref"}), maternal age\>40 years (Herkrath et al., [2012](#bdra23540-bib-0023){ref-type="ref"}), and zinc deficiency (Warkany and Petering, [1972](#bdra23540-bib-0058){ref-type="ref"}).

Our results also suggested that the *IRF6* ((i.e., rs2235371, rs2013162, rs642961) and 8q24 (rs987525) SNPs contributed to NSCL/P, in which the rs987525 had highest contribution. This might be comparable to the effect of folate with an estimated PAR approximately 18% (van Rooij et al., 2004; Kelly et al., [2012](#bdra23540-bib-0034){ref-type="ref"}). For public health prevention, screening these genes and other genes identified by previous meta‐analyses (e.g., *VAX1*, Figueiredo et al., [2014](#bdra23540-bib-0018){ref-type="ref"}; or bone morphogenetic protein 4, Hu et al., [2015](#bdra23540-bib-0026){ref-type="ref"}), and combining them with environmental factors (e.g., folate, alcohol, etc.) may lead to a useful risk score for prediction of NSCL/P occurrence (Seddon et al., [2009](#bdra23540-bib-0064){ref-type="ref"}).

Our study has some strengths. We attempted to pool variant effects on NSCL/P separately by ethnicity if data were available. Prevalence of MAFs for each study polymorphism was pooled across studies and ethnicity. Mode of variant effect was estimated using a mixed‐effect logistic regression (Thakkinstian et al., 2005a) to capture lambda (Minelli et al., [2005](#bdra23540-bib-0045){ref-type="ref"}). However, our study also has some limitations. First, given that we worked on summary data, we could not control for confounding effects, although the major source of confounding for genetic studies is population stratification and we summarized results by ethnic group. Second, we could only identify association between genes and NSCL/P, and we do not know whether the genes directly affect NSCL/P or whether their effects might be exerted through other environmental factors, such as folate. Exploring this would require individual patient data where data for folate and other co‐variables are also available. Third, we could not identify which polymorphism is the disease gene among those three polymorphisms in *IRF6* gene because evidences showed linkage disequilibrium between rs2235371 and rs2013162 in Mexican (Ibarra‐Arce et al., [2015](#bdra23540-bib-0028){ref-type="ref"}) and Chinese (Mijiti et al., [2015](#bdra23540-bib-0044){ref-type="ref"}) population (r^2^ = 0.39 and 0.25, respectively) but not for rs642961 (Pan et al., [2010](#bdra23540-bib-0050){ref-type="ref"}) (r^2^ = 0.07). To determine this required raw data for performing a haplotype analysis. Some variant effects were heterogeneous (i.e., varied) across studies; we could explore for a cause of heterogeneity by fitting percent male in a meta‐regression, but this was not detected (data were not shown). There might be other characteristics that cause heterogeneity, but those data were not available. Finally, there might be gene to gene interactions, but summary data do not allow us to explore this.

Conclusions {#bdra23540-sec-0021}
-----------

All polymorphisms, rs2235371, rs2013162, and rs642961 at *IRF6* and rs987525 in 8q24 were significantly associated with NSCL/P. However, after applying Bonferroni corrected‐thresholds, variant effects remained significant, except in mixed ethnicity. We show robust variant effects in NSCL/P. Including them with other risk factors and other genes in a risk prediction model of NSCL/P might be useful to improve prediction of NSCL/P occurrence.
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